Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER)

Real-world data from the ERN RARE LIVER registry highlight current practices in PBC management and reveal opportunities to optimise care for higher-risk patients.

Back to overview

This multicentre observational prospective study from the ERN RARE LIVER R-LIVER registry provides real-world insights into PBC. Among 316 patients included in the treatment analysis, UDCA was initiated in 98.7%, with inadequate response rates of 14.9% (Toronto) and 22.3% (POISE), and ALP normalization achieved in 49.5%. Worse baseline liver biochemistry was associated with inadequate response, yet only 41.9% of Toronto non-responders received second-line therapy. Adherence to EASL recommendations was high. The study shows fewer inadequate responders than historical data but stresses the need to improve second-line therapy use in higher-risk patients.

The full publication is available here.